A very good H1 update from CVS this morning. Sales growth is reported at 11.4% with LFL’s of c.10%, EBITDA up a strong 15.5% and H2 has got off to a good start. In short, another period of excellent delivery. We push through a 3.5% EPS upgrade for the current year and tick up outer year forecasts by 2%. The stage one deadline for the CMA to report on the Quality Pet Care deal is 18th Feb’22. There are a range of theoretical outcomes (no case to answer, divest some of the 8 practices, or divest a ....
27 Jan 2022
H1 update - another period of excellent delivery; upgrades
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 update - another period of excellent delivery; upgrades
CVS Group plc (CVSG:LON) | 954 104.9 1.2% | Mkt Cap: 684.2m
- Published:
27 Jan 2022 -
Author:
Sahill Shan -
Pages:
4
A very good H1 update from CVS this morning. Sales growth is reported at 11.4% with LFL’s of c.10%, EBITDA up a strong 15.5% and H2 has got off to a good start. In short, another period of excellent delivery. We push through a 3.5% EPS upgrade for the current year and tick up outer year forecasts by 2%. The stage one deadline for the CMA to report on the Quality Pet Care deal is 18th Feb’22. There are a range of theoretical outcomes (no case to answer, divest some of the 8 practices, or divest a ....